Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn's recent shareholder activity highlights a period of significant expansion and strategic investment, though not without some investor caution. The company's 45th Annual General Meeting approved key resolutions including dividend declaration and a preferential issue for fundraising, alongside re-appointments of directors and amendments to the articles of association. Notably, a resolution seeking approval for promoter loans was rejected, suggesting shareholder reservations regarding the company’s increasing debt load, which rose substantially year-over-year to finance capacity expansions and acquisitions like Sanofi’s portfolio and MicroBiopharm. With post-balance sheet acquisitions totaling ₹2,800 crore, investors should monitor the company’s ability to effectively integrate these assets and manage its elevated debt levels to sustain growth.